Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL
doi: 10.3390/biology11030389 310 YaroshkoO.PasternakT.LarribaE.Prez-PrezJ
Oh TJ, Song Y, Jang HC, Choi SH
This mechanism facilitates the controlled release of various therapeutic agents, including chemotherapeutics, photosensitizers, sonosensitizers, peptides, proteins, and nucleic acids
Normal levels of both methylmalonic acid and total homocysteine almost certainly rule out clinically significant cobalamin deficiency (Savage et al., 1994)
Hara M et al
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
US$ 22.24
US$ 29.15
US$ 21.89
US$ 23.64
